Tanvex BioPharma Inc (6541) — Cash Flow-to-Debt Ratio
Tanvex BioPharma Inc (6541) has a Cash Flow-to-Debt Ratio of -0.14x as of March 2026, meaning its operating cash flow of NT$-309.37 Million could theoretically repay 0% of its total liabilities (NT$2.27 Billion) in one year. Explore 6541 cash flow conversion to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tanvex BioPharma Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Tanvex BioPharma Inc across 13 annual periods. Also explore 6541 total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Tanvex BioPharma Inc (2013–2025)
Year-by-year debt coverage analysis for Tanvex BioPharma Inc. For market capitalisation and broader financial context, see market value of Tanvex BioPharma Inc.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.44x | NT$-1.01 Billion | NT$2.27 Billion | ▲ +29.0% |
| 2024 | -0.62x | NT$-1.15 Billion | NT$1.84 Billion | ▲ +15.4% |
| 2023 | -0.74x | NT$-1.43 Billion | NT$1.94 Billion | ▼ -12.3% |
| 2022 | -0.66x | NT$-1.33 Billion | NT$2.03 Billion | ▲ +9.0% |
| 2021 | -0.72x | NT$-1.39 Billion | NT$1.92 Billion | ▲ +29.2% |
| 2020 | -1.02x | NT$-1.79 Billion | NT$1.75 Billion | ▲ +70.9% |
| 2019 | -3.50x | NT$-1.90 Billion | NT$542.12 Million | ▲ +42.4% |
| 2018 | -6.08x | NT$-1.61 Billion | NT$263.92 Million | ▼ -12.3% |
| 2017 | -5.42x | NT$-1.21 Billion | NT$223.78 Million | ▼ -94.5% |
| 2016 | -2.79x | NT$-833.43 Million | NT$299.25 Million | ▲ +50.6% |
| 2015 | -5.64x | NT$-684.20 Million | NT$121.41 Million | ▲ +15.5% |
| 2014 | -6.67x | NT$-434.17 Million | NT$65.09 Million | ▼ -132.5% |
| 2013 | -2.87x | NT$-239.86 Million | NT$83.63 Million | — |